3006 POSTER DISCUSSION Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)
2011 ◽
Vol 47
◽
pp. S224
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. 4504-4504
◽
2011 ◽
Vol 5
(3)
◽
pp. 211-221
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. 4503-4503
◽
Keyword(s):
2017 ◽
Vol 15
(6)
◽
pp. e1081-e1088
◽
Keyword(s):
2016 ◽
Vol 14
(6)
◽
pp. e595-e607
◽
Keyword(s):
2000 ◽
Vol 11
(3)
◽
pp. 175-179
◽
Keyword(s):